180 related articles for article (PubMed ID: 37457135)
1. Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance.
Jiang Y; Donati V; Peters GJ; Giovannetti E; Deng DM
Cancer Drug Resist; 2023; 6(2):284-290. PubMed ID: 37457135
[TBL] [Abstract][Full Text] [Related]
2. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer.
Alam A; Levanduski E; Denz P; Villavicencio HS; Bhatta M; Alhorebi L; Zhang Y; Gomez EC; Morreale B; Senchanthisai S; Li J; Turowski SG; Sexton S; Sait SJ; Singh PK; Wang J; Maitra A; Kalinski P; DePinho RA; Wang H; Liao W; Abrams SI; Segal BH; Dey P
Cancer Cell; 2022 Feb; 40(2):153-167.e11. PubMed ID: 35120601
[TBL] [Abstract][Full Text] [Related]
3. The mycobiome-immune axis: The next frontier in pancreatic cancer.
Li X; Saxena D
Cancer Cell; 2022 Feb; 40(2):120-122. PubMed ID: 35167821
[TBL] [Abstract][Full Text] [Related]
4. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
7. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
9. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
Front Oncol; 2020; 10():621937. PubMed ID: 33520728
[TBL] [Abstract][Full Text] [Related]
10. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
[TBL] [Abstract][Full Text] [Related]
11. KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages.
Li MX; Wang HY; Yuan CH; Ma ZL; Jiang B; Li L; Zhang L; Xiu DR
Clin Sci (Lond); 2021 Feb; 135(4):629-649. PubMed ID: 33538300
[TBL] [Abstract][Full Text] [Related]
12. Fungal ablation and transplantation of specific fungal species into PDAC tumor-bearing mice.
Alam A; Comer S; Levanduski E; Dey P
STAR Protoc; 2022 Sep; 3(3):101644. PubMed ID: 36052343
[TBL] [Abstract][Full Text] [Related]
13. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.
Yang H; Zhang W; Ding J; Hu J; Sun Y; Peng W; Chu Y; Xie L; Mei Z; Shao Z; Xiao Y
Front Immunol; 2022; 13():970588. PubMed ID: 36148233
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold.
Rubin SJS; Sojwal RS; Gubatan J; Rogalla S
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077772
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
16. A new era: tumor microenvironment in chemoresistance of pancreatic cancer.
Zhao X; Li Z; Gu Z
J Cancer Sci Clin Ther; 2022; 6(1):61-86. PubMed ID: 35187493
[TBL] [Abstract][Full Text] [Related]
17. Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development.
Bellotti R; Speth C; Adolph TE; Lass-Flörl C; Effenberger M; Öfner D; Maglione M
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298645
[TBL] [Abstract][Full Text] [Related]
18. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
19. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma.
Liu X; Liu J; Xu J; Zhang B; Wei M; Li J; Xu H; Yu X; Wang W; Shi S
Transl Oncol; 2023 Jan; 27():101561. PubMed ID: 36257208
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts.
Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R
Cells; 2021 Jul; 10(7):. PubMed ID: 34359823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
